| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (health, clinical) | 74 |
| Education & TrainingMatches your industry (stem) | 66 |
| Arts & CultureLimit: Nothing in this notice points to arts & culture | 54 |
| Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech | 54 |
| Environment & ConservationLimit: Nothing in this notice points to environment & conservation | 54 |
| Finance & BankingLimit: Nothing in this notice points to finance & banking | 54 |
| Industry | Estimated fit |
|---|---|
| Housing & Real EstateLimit: Nothing in this notice points to housing & real estate | 54 |
| Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce | 54 |
| Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit | 54 |
| Technology & SoftwareLimit: Nothing in this notice points to technology & software | 54 |
| Agriculture & FarmingLimit: Nothing in this notice points to agriculture & farming | 53 |
| Construction & InfrastructureMatches your industry (building) | 51 |
| Food & BeverageLimit: Nothing in this notice points to food & beverage | 51 |
| ManufacturingLimit: Nothing in this notice points to manufacturing | 49 |
| Transportation & LogisticsLimit: Nothing in this notice points to transportation & logistics | 48 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH Common Fund SenNet Stage 2 Discovery and Validation Centers will define, refine, and validate cellular senescence signatures (senotypes) and biomarkers in human health and disease, generating molecular, cellular, and spatial datasets. Open to universities, nonprofits, small and other for-profit businesses, governments, tribes, and other organizations; clinical trials not allowed.
The purpose of this Notice of Funding Opportunity (NOFO) is to support SenNet Discovery and Validation Centers (SenNet DVCs) as a core component of Stage 2 of the NIH Common Fund Cellular Senescence Network (SenNet). Building on Stage 1 resources, DVCs will define, refine, and validate tissue- and disease-relevant cellular senescence signatures (“senotypes”) and associated biomarkers, and will investigate their functional consequences in human health and disease. DVCs are expected to generate and contribute high-quality molecular, cellular, and spatial datasets (including relevant metadata and documentation) and to use complementary experimental systems, as appropriate, to validate senotypes/biomarkers and characterize responses to senescence-associated perturbations or senotherapeutic approaches. DVC applications should also propose goals and aims for SenNet consortium-wide organizational and outreach activities (SenNet OOC functions).
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…